Cantor Fitzgerald Reiterates Buy Rating for Healthequity (NASDAQ:HQY)

Cantor Fitzgerald reiterated their buy rating on shares of Healthequity (NASDAQ:HQY) in a report published on Tuesday, December 5th. They currently have a $56.00 target price on the stock.

Several other research analysts have also recently issued reports on the company. Zacks Investment Research raised Healthequity from a hold rating to a buy rating and set a $58.00 price target on the stock in a report on Wednesday, October 11th. BidaskClub downgraded shares of Healthequity from a hold rating to a sell rating in a research note on Wednesday, October 18th. Oppenheimer reissued a buy rating and set a $61.00 target price on shares of Healthequity in a research note on Wednesday, September 6th. Chardan Capital boosted their target price on shares of Healthequity from $58.00 to $62.00 and gave the company a buy rating in a research note on Wednesday, December 6th. Finally, Robert W. Baird reissued a hold rating on shares of Healthequity in a research note on Thursday, September 21st. Three investment analysts have rated the stock with a hold rating and eight have issued a buy rating to the stock. Healthequity currently has an average rating of Buy and a consensus target price of $58.33.

Shares of Healthequity (NASDAQ HQY) traded down $0.73 during mid-day trading on Tuesday, hitting $46.66. 323,404 shares of the company traded hands, compared to its average volume of 545,952. The company has a market cap of $2,830.00, a P/E ratio of 63.05, a price-to-earnings-growth ratio of 1.95 and a beta of 1.74. Healthequity has a 1-year low of $37.62 and a 1-year high of $55.31.

Healthequity (NASDAQ:HQY) last posted its quarterly earnings results on Tuesday, December 5th. The company reported $0.17 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $0.13 by $0.04. The company had revenue of $56.80 million for the quarter, compared to analysts’ expectations of $55.27 million. Healthequity had a return on equity of 14.47% and a net margin of 21.08%. The firm’s revenue was up 31.0% on a year-over-year basis. During the same quarter in the prior year, the company earned $0.10 earnings per share. equities research analysts forecast that Healthequity will post 0.71 EPS for the current year.

In other news, Director Frank Medici sold 419,504 shares of the company’s stock in a transaction on Monday, November 6th. The shares were sold at an average price of $52.97, for a total value of $22,221,126.88. Following the transaction, the director now directly owns 6,381 shares of the company’s stock, valued at $338,001.57. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, VP Darcy G. Mott sold 9,500 shares of the company’s stock in a transaction on Wednesday, December 20th. The stock was sold at an average price of $47.91, for a total transaction of $455,145.00. Following the completion of the transaction, the vice president now directly owns 96,500 shares in the company, valued at $4,623,315. The disclosure for this sale can be found here. Insiders sold 1,761,117 shares of company stock worth $91,915,316 over the last ninety days. 29.00% of the stock is currently owned by company insiders.

A number of large investors have recently modified their holdings of the stock. BlackRock Inc. boosted its holdings in Healthequity by 4.3% in the second quarter. BlackRock Inc. now owns 5,831,014 shares of the company’s stock worth $290,559,000 after purchasing an additional 241,061 shares in the last quarter. Vanguard Group Inc. boosted its holdings in Healthequity by 3.0% in the second quarter. Vanguard Group Inc. now owns 4,237,298 shares of the company’s stock worth $211,145,000 after purchasing an additional 122,061 shares in the last quarter. Wasatch Advisors Inc. boosted its holdings in Healthequity by 2.2% in the second quarter. Wasatch Advisors Inc. now owns 2,442,180 shares of the company’s stock worth $121,694,000 after purchasing an additional 52,885 shares in the last quarter. FMR LLC boosted its holdings in Healthequity by 45.6% in the second quarter. FMR LLC now owns 2,235,150 shares of the company’s stock worth $111,378,000 after purchasing an additional 699,728 shares in the last quarter. Finally, Janus Henderson Group PLC boosted its holdings in Healthequity by 627.9% in the second quarter. Janus Henderson Group PLC now owns 2,113,030 shares of the company’s stock worth $105,292,000 after purchasing an additional 1,822,732 shares in the last quarter. Hedge funds and other institutional investors own 98.27% of the company’s stock.

COPYRIGHT VIOLATION NOTICE: “Cantor Fitzgerald Reiterates Buy Rating for Healthequity (NASDAQ:HQY)” was first reported by Week Herald and is the property of of Week Herald. If you are reading this piece on another website, it was stolen and reposted in violation of U.S. & international copyright and trademark law. The correct version of this piece can be read at https://weekherald.com/2017/12/30/healthequity-hqy-rating-reiterated-by-cantor-fitzgerald.html.

Healthequity Company Profile

HealthEquity, Inc provides a range of solutions for managing healthcare accounts (Health Savings Accounts (HSAs), Health Reimbursement Arrangements (HRAs) and Flexible Spending Accounts (FSAs)) for health plans, insurance companies and third-party administrators. The Company is engaged in technology-enabled services platforms that allow consumers to make healthcare saving and spending decisions.

Analyst Recommendations for Healthequity (NASDAQ:HQY)

Receive News & Ratings for Healthequity Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Healthequity and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply